Opening and Closing Bell on Wall Street
Executives and guests of Medgenics, Inc. (NYSE Amex: MDGN) visited the New York Stock Exchange (NYSE Amex) to celebrate the company’s April 8th, 2011 Listing. President, CEO, and Founder, Dr. Andrew Pearlman Ph.D. rang The Closing Bell.
Medgenics is developing and commercializing the Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins.